Armistice Capital, LLC Eagle Pharmaceuticals, Inc. Transaction History

Armistice Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $3.05 Million - $3.8 Million	-74,000 Reduced 33.04%	150,000 $6.67 Million
Q1 2022 May 16, 2022	BUY	$44.58 - $52.6 $9.99 Million - $11.8 Million	224,000 New	224,000 $11.1 Million
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $7.08 Million - $8.54 Million	-192,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$40.32 - $50.97 $6.94 Million - $8.77 Million	-172,000 Reduced 47.25%	192,000 $8.01 Million
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $12.8 Million - $15.8 Million	-308,000 Reduced 45.83%	364,000 $17 Million
Q3 2020 Nov 16, 2020	BUY	$37.02 - $51.28 $14.4 Million - $20 Million	390,000 Added 138.3%	672,000 $28.5 Million
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $12.2 Million - $15.5 Million	282,000 New	282,000 $13.5 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.